SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aster DM Healthcare surges as its arm enters into JVA with Abdulmohsen Al Hokair Holding Group

18 Oct 2022 Evaluate

Aster DM Healthcare is currently trading at Rs 249.65, up by 7.35 points or 3.03% from its previous closing of Rs. 242.30 on the BSE.

The scrip opened at Rs. 247.05 and has touched a high and low of Rs. 251.60 and Rs. 247.05 respectively. So far 39024 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 265.55 on 11-Oct-2022 and a 52 week low of Rs. 158.00 on 07-Mar-2022.

Last one week high and low of the scrip stood at Rs. 265.55 and Rs. 231.80 respectively. The current market cap of the company is Rs. 12487.83 crore.

The promoters holding in the company stood at 37.88 % while Institutions and Non-Institutions held 20.76 % and 41.36 % respectively.

Aster DM Healthcare’s material subsidiary -- Aster Pharmacies Group LLC (Aster Pharmacy) has entered into a Joint Venture agreement (JVA) with Abdulmohsen Al Hokair Holding Group on October 16, 2022 to establish, manage and operate Pharmacy chain across the Kingdom of Saudi Arabia (KSA) to market and commercialize pharmaceutical products within each Pharmacy under the ‘Aster Pharmacy’ brand. Through this JV agreement, both the partners will work towards bringing Aster Pharmacy’s in-house quality care products to serve the healthcare needs of the local population in KSA.

Aster DM Healthcare operates as a healthcare company in the Middle East, India, and the Far East. It operates hospitals and clinics, pharmacies, diagnostic centers, educational institutions, and healthcare management and healthcare support systems.

Aster DM Healthcare Share Price

688.30 13.15 (1.95%)
17-Apr-2026 16:59 View Price Chart
Peers

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×